Taipei, Taiwan
Taipei, Taiwan

Time filter

Source Type

Patent
Everfront Biotech Inc. | Date: 2017-03-01

A stable pharmaceutical composition, containing: (a) a medium system, containing a first component, a second component, and a third component, wherein the first component is a phosphate buffer solution; the second component is selected from the group consisting of: vegetable oils, animal oils, fatty acids and a combination thereof; and the third component is selected from the group consisting of: polyethylene glycol, dimethyl sulfoxide, ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, hydroxyethyl 12-hydroxy stearate, vitamin E, polyethylene glycol succinate, and a combination thereof, and (b) n-butylidenephthalide (BP).


Patent
Everfront Biotech Inc. | Date: 2017-05-10

Disclosed is a use of phthalide compound for the preparation of a medicament. The medicament is especially used for treating and/or delaying the degeneration of Purkinje cells, and the phthalide compound is selected from the following group: butylidene phthalide, a metabolic precursor of butylidene phthalide, a pharmaceutically acceptable salt of the metabolic precursor of butylidene phthalide, a pharmaceutically acceptable ester of the metabolic precursor of butylidene phthalide, and any combination of the foregoing.


Chan T.-M.,China Medical University at Taichung | Chan T.-M.,Everfront Biotech Inc | Harn H.-J.,China Medical University at Taichung | Lin H.-P.,National Health Research Institute | And 17 more authors.
Cell Transplantation | Year: 2014

Human mesenchymal stem cells (hMSCs) are currently available for a range of applications and benefits and have become a good material for regenerative medicine, tissue engineering, and disease therapy. Before ex vivo expansion, isolation and characterization of primary hMSCs from peripheral tissues are key steps for obtaining adequate materials for clinical application. The proportion of peripheral stem cells is very low in surrounding tissues and organs; thus the recovery ratio will be a limiting factor. In this review, we summarized current common methods used to isolate peripheral stem cells, as well as the new insights revealed to improve the quantity of stem cells and their stemness. These strategies offer alternative ways to acquire hMSCs in a convenient and/ or effective manner, which is important for clinical treatments. Improved isolation and mass amplification of the hMSCs while ensuring their stemness and quantity will be an important step for clinical use. Enlarged suitable hMSCs are more clinically applicable for therapeutic transplants and may help people live longer and better. © 2014 Cognizant Comm. Corp.


Ho T.-J.,China Medical University at Taichung | Ho T.-J.,China Medical University Beigang Hospital | Chan T.-M.,China Medical University at Taichung | Chan T.-M.,Everfront Biotech Inc | And 10 more authors.
Cell Transplantation | Year: 2014

This review reports on recent findings concerning the effects of acupuncture and electroacupuncture (EA) on stem cell mobilization and differentiation, in particular with regard to neurogenesis. Traditional Chinese acupuncture has a history of over 2,500 years and is becoming more popular worldwide. Evidence has demonstrated that acupuncture may be of benefit in stroke rehabilitation, parkinsonism, dementia, and depression. This article reviews recent studies concerning the effects of acupuncture/EA on stem cell mobilization and on progenitor cell proliferation in the CNS. The reviewed evidence indicates that acupuncture/EA has beneficial effects in several neurodegenerative diseases, and it may prove to be a nondrug method for mobilizing stem cells in the CNS. © 2014 Cognizant Comm. Corp.


Chan T.-M.,China Medical University at Taichung | Chan T.-M.,Everfront Biotech Inc | Harn H.-J.,China Medical University at Taichung | Lin H.-P.,National Health Research Institute | And 11 more authors.
Cell Transplantation | Year: 2014

Stroke is one of the disorders for which clinically effective therapeutic modalities are most needed, and numerous ways have been explored to attempt to investigate their feasibilities. However, ischemic- or hemorrhagicinduced inflammatory neuron death causes irreversible injuries and infarction regions, and there are currently no truly effective drugs available as therapy. It is therefore urgent to be able to provide a fundamental treatment method to regenerate neuronal brain cells, and therefore, the use of stem cells for curing chronic stroke could be a major breakthrough development. In this review, we describe the features and classification of stroke and focus on the benefits of adipose tissue-derived stem cells and their applications in stroke animal models. The results show that cell-based therapies have resulted in significant improvements in neuronal behaviors and functions through different molecular mechanisms, and no safety problems have so far arisen after transplantation. Further, we propose a clinical possibility to create a homing niche by reducing the degree of invasive intracerebroventricular transplantation and combining it with continuous intravenous administration to achieve a complete cure. © 2014 Cognizant Comm. Corp.


Chan T.-M.,China Medical University at Taichung | Chan T.-M.,Everfront Biotech Inc | Chen J.Y.-R.,Guang Li Biomedicine Inc | Ho L.-I.,Taipei Veterans General Hospital | And 14 more authors.
Cell Transplantation | Year: 2014

Neurodegenerative disorders, chronic diseases that can severely affect the patient's daily life, include amyotrophic lateral sclerosis, Parkinson's, Alzheimer's, and Huntington's diseases. However, these diseases all have the common characteristic that they are due to degenerative irreversibility, and thus no efficient drugs or therapy methods can mitigate symptoms completely. Stem cell therapy, such as adipose tissue-derived stem cells (ADSCs), is a promising treatment for incurable disorders. In this review, we summarized the previous studies using ADSCs to treat neurodegenerative disorders, as well as their therapeutic mechanisms. We also suggested possible expectations for future human clinical trials involving minimized intracerebroventricular combined with intravenous administration, using different cell lineages to finish complementary therapy as well as change the extracellular matrix to create a homing niche. Depending on successful experiments in relevant neurodegenerative disorders models, this could form the theoretical basis for future human clinical trials. © 2014 Cognizant Comm. Corp.


Huang M.-H.,National Chung Hsing University | Lin S.-Z.,China Medical University at Taichung | Lin S.-Z.,China Medical University Beigan Hospital | Lin P.-C.,Applied Cell Technology | And 10 more authors.
Tumor Biology | Year: 2014

Developing an effective drug for treating human glioblastoma multiform (GBM) has been investigated persistently. A pure compound butylidenephthalide (BP), isolated from Angelica sinensis, has been shown the activities to arrest the growth and initiate apoptosis of GBM in our previous reports. In this study, we further demonstrated that BP treatment accelerates the cell senescence in a dose-dependent manner in vitro and in vivo. S-phase kinase-associated protein 2 (Skp2), a proto-oncogene, is generally upregulated in cancer. We found that it was downregulated in BP-treated GBM cells. The downregulation of Skp2 is parallel with increasing p16 and p21 expression which causes G0/G1 arrest and tumor cell senescence. We also found that restoring the Skp2 protein level by exogenous overexpression prevents the BP-induced cell senescence. Therefore, the linkage between cell senescence and Skp2 expression is strengthened. Promoter binding analysis further detailed that the BP-mediated SP1 reduction might involve in the Skp2 downregulation. In summary, these results emphasize that BP-triggered senescence in GBMcells is highly associated with its control on Skp2 regulation. © International Society of Oncology and BioMarkers (ISOBM) 2014.


Chiu S.-C.,China Medical University at Taichung | Chung H.-Y.,China Medical University at Taichung | Chung H.-Y.,China Medical University Beigan Hospital | Cho D.-Y.,China Medical University at Taichung | And 12 more authors.
Cell Transplantation | Year: 2014

The first microRNA, let-7, and its family were discovered in Caenorhabditis elegans and are functionally conserved from worms to humans in the regulation of embryonic development and stemness. The let-7 family has been shown to have an essential role in stem cell differentiation and tumor-suppressive activity. Deregulating expression of let-7 is commonly reported in many human cancers. Emerging evidence has accumulated and suggests that reestablishment of let-7 in tumor cells is a valuable therapeutic strategy. However, findings reach beyond tumor therapeutics and may impinge on stemness and differentiation of stem cells. In this review, we discuss the role of let-7 in development and differentiation of normal adult stem/progenitor cells and offer a viewpoint of the association between deregulated let-7 expression and tumorigenesis. The regulation of let-7 expression, cancer-relevant let-7 targets, and the application of let-7 are highlighted. © 2014 Cognizant Comm. Corp.

Loading Everfront Biotech Inc collaborators
Loading Everfront Biotech Inc collaborators